AnPac Bio’s Bio-Chip Subsidiary, Changwei System Technology Co., Ltd., Receives Independent Valuation and Approval from the Board to Explore Strategic Alternatives
Retrieved on:
Thursday, March 3, 2022
Risk, Gu Changwei, Motorola, Patient, Semiconductor Manufacturing International Corporation, RMB, Amkor Technology, IC, Frost, Ministry, Knowledge, CDA, CLIA, Board, Letter, IVD, Company, IP, CEO, CAP, Frost & Sullivan, Diabetes, R, Disclosure, Ministry of Finance (Malaysia), Micron Technology, GLOBE, Mobile phone
The appraisal was performed following the recent approval from the board of directors of AnPac Bio to explore strategic alternatives for Changwei, including a potential strategic investment, to maximize shareholder value for the Company.
Key Points:
- The appraisal was performed following the recent approval from the board of directors of AnPac Bio to explore strategic alternatives for Changwei, including a potential strategic investment, to maximize shareholder value for the Company.
- Changwei was founded in 2011 and has since focused on thedesign, R&D, and testingof novel, specialty bio-integrated circuit (IC) chips for life science applications.
- There can be no assurance that the strategic review process will result in any strategic alternative, or any assurance as to its outcome or timing.
- AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 150 issued patents as of September 30, 2021.